Kornimate/medical-research-clean huggingface dataset:
combination of orbital compression surgery and strabismus surgery for thyroid associated ophthalmopathy

Conditions: Thyroid Associated Ophthalmopathy

Summary: the purpose of this study is to determine whether combination of orbital compression surgery with strabismus surgery is better than strabismus surgery after orbital compression surgery in the treatment of moderate-to-severe thyroid associated ophthalmopathy

this study will be a interventional case series. patients with moderate-to-severe thyroid associated ophthalmopathy will be randomized to receive combination of orbital compression surgery with strabismus surgery or strabismus surgery after orbial compression surgery.patients will be followed for 6 months.

Eligibility criteria:
inclusion criteria: * moderate-to-severe thyroid associate ophthalmopathy * cas≤3 score * monocular strabismus,deviation≥20° or 35▲ * stable thyroid function for at least 6 months, confirmed by an endocrinologist exclusion criteria: * any previous disease in the study eye. * any previous systematic disease
eva nexus vitrectomy device field observation study

Conditions: Retina Disorder; Vitreous Disorder

Summary: determine the safety and effectiveness of the device.

to perform a field observation study using the newly developed eva nexus vitrectomy device. patients that are scheduled for intra-ocular surgery regardless of the indication: * vitrectomy surgery * cataract surgery * vitrectomy combined with cataract surgery

Eligibility criteria:
inclusion criteria: * patients that are scheduled for intra-ocular surgery regardless of the indication: * vitrectomy surgery * cataract surgery * vitrectomy combined with cataract surgery * in case of (combined) vitrectomy: primary or repeat vitrectomy * general or retrobulbar anesthesia, the latter can be combined with sedation * patients aged ≥ 18 years exclusion criteria: * patients aged \< 18 years
bleb vascularity change after subconjunctival injection bevacizumab

Conditions: Bleb Vascularity; Conjunctival Scarring

Summary: the occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. so it seems that the recombinant human anti-vegf antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.


Eligibility criteria:
inclusion criteria: * glaucoma patients after trabeculectomy whose bleb is hyperaemia exclusion criteria: * affected eye has normal iop * not allergic with avastin

Keywords: bleb vascular change bevacizumab trabeculectomy bleb vascularity associated with increased scarring activity conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery the recombinant human anti-vegf antibody could inhibit angiogenesis of conjunctiva.
snack food reinforcement in obese and non-obese women

Conditions: Obesity

Summary: food reinforcement, motivation to obtain food, is associated with energy intake and obesity. finding ways to decrease the reinforcing value of unhealthy foods may help with adherence to diets and weight loss. our previous study in non-obese adults showed that daily consumption of the same snack food (food typically consumed outside of meals) for 14 days significantly decreased its reinforcing value. the purpose of this study was to replicate and extend these findings to obese individuals as well as to examine effects of different portion sizes of snack foods on food reinforcement. thirty-one obese (body mass index \> 30 kg/m2) and 27 non-obese (bmi \< 30 kg/m2) women had food reinforcement and liking tested at baseline and after two weeks of daily consumption of either 0 kcal, 100 kcals, or 300 kcals daily of the same snack food.


Eligibility criteria:
inclusion criteria: * women * non-smoker * not on a diet * no restrained eating * had to like potential snack foods * willing to visit the laboratory 3 times * willing to eat snacks provided * no medications or medical conditions that affect appetite * no food allergies exclusion criteria: * see above

Keywords: bmi obesity sensitization food reinforcement snack food portion size of daily snacks weight status
acupuncture and post-surgical wound healing

Conditions: Postoperative Complications; Surgical Wound Infection; Surgical Wound Dehiscence

Summary: the purpose of this study is to determine if acupuncture improves wound healing. since we, the investigators at the university of california, san francisco (ucsf), know that how much oxygen is delivered to tissue is the best predictor of how well a wound will heal, we are measuring changes in tissue oxygen of wounds before and after acupuncture treatments. we are focusing on the leg wounds of coronary artery bypass graft (cabg) patients who have their saphenous veins harvested in an open fashion since this is a fairly well controlled patient model.

this is a prospective, randomized, controlled pilot study of the effects of acupuncture on surgical site complications in patients undergoing coronary artery bypass grafting. the past forty years of research in the ucsf wound healing laboratory have solidified the following observations: 1. without adequate oxygen delivery, many processes of wound healing cannot proceed normally, particularly resistance to infection, collagen deposition, angiogenesis, and inflammation; and 2. hypoxic conditions, unfortunately, are common in chronic and acute wounds, and often result from subcutaneous vasoconstriction. sympathetic nervous system (sns) activators and other vasoconstrictors have been shown to produce wound hypoxia. activation of the sns by any means, including pain and anxiety, causes vasoconstriction and impairs oxygen delivery. simple means that limit sns activity have been shown to increase perfusion and oxygen tension, and thereby facilitate wound healing. many preliminary studies have shown that acupuncture decreases sns activation, pain, and anxiety. in addition, there is evidence that acupuncture enhances circulation of blood. we therefore hypothesize that acupuncture will facilitate wound healing. we aim to quantify changes in anxiety, pain, stress hormones, and perfusion and oxygenation induced by these interventions, as well as wound healing outcomes, including infection and other wound complications.

Eligibility criteria:
inclusion criteria: * adults (age \> 18) * males/females * all races * elective/urgent cabg * open saphenous vein graft harvest * university of california, san francisco, and additional approved hospital sites exclusion criteria: pre-operative * emergent cabg, valves * history of peripheral vascular surgery, amputation, severe peripheral neuropathy, immunocompromise, or end-stage renal disease requiring hemodialysis post-operative * postoperative day 1 (pod1) hemodynamic instability * ≥ 4u packed red blood cells transfusion (prbc)/8 hours, ct \> 200cc/hour 3 hours, \> 2 pressors * prolonged intubation (\> pod1) * altered mental status

Keywords: cardiac surgical procedures open saphenous vein graft harvest wounds postoperative complications surgical wound infection surgical wound dehiscence
innate immunity in hiv positive patients co-infected with hepatitis c virus (hcv) or hepatitis b virus (hbv)

Conditions: HIV-hepatitis Co-infection; HIV Infections

Summary: data from this study will provide the first information how the innate immune system may be altered in hiv-hcv and hiv-hbv co-infected individuals, and describe toll-like receptor changes with hiv co-infection therapy.

it has been demonstrated that toll-like receptors (tlr) are involved in viral hepatitis - hepatitis b (hbv), hepatitis c (hcv) - and hiv in the setting of mono-infection. however the role of innate immunity in the pathogenesis of hiv-hepatitis co-infection in both natural and therapy-associated viral clearance remains unclear. the data from this study may reveal patterns which could predict how and when patients spontaneously, and with therapy, resolve hbv or hcv in the setting of co-infection. the aim of the study is to evaluate the activity of innate immunity in different subsets of hiv-infected populations co-infected with chronic hepatitis b and/or c. our hypothesis is that innate immunity is altered in hiv and hepatitis co-infection and that this differs from both hepatitis and hiv mono-infection. the study is a cross-sectional and longitudinal pilot study of individuals infected with hiv and either hbv or hcv.

Eligibility criteria:
inclusion criteria: * hiv and either hbv or hcv co-infection * 18 years and older * able to give informed consent exclusion criteria: * hiv-hbv-hcv triple infection

Keywords: hiv hbv hcv co-infection innate immunity
fixating the plate of ahmed valve to the sclera using a flanged prolene suture

Conditions: Glaucoma

Summary: this study evaluated new technique for suturing the ahmed valve device used to treat resistant types of glaucoma

this technique of fixating ahmed glaucoma valve using flanged prolene suture is an safe, fast, and reproducible technique combines the benefits of fixing the plate with excellent stability with no complications of free plate techniques at the same time, decreasing both the risks of old valve plate fixation techniques and the concerns of the relative technical difficulty

Eligibility criteria:
inclusion criteria: * patients with iop more than 21 mmhg , evidence of progressive optic nerve damage, retinal nerve fiber layer defects or typical glaucomatous visual field defects despite maximal tolerable medical or laser treatment are scheduled for surgery. exclusion criteria: * the exclusion criteria were as follows: patients below 18 years old, those with active uveitis and angle closure glaucoma patients.

Keywords: ahmed glaucoma valve, prolene, glaucoma drainage device
data analysis and physical function evaluation index development for early diagnosis and monitoring of icu-acquired weakness

Conditions: Cohort Studies; ICU Acquired Weakness (ICUAW); Critical Illness

Summary: data analysis and physical function evaluation index development for early diagnosis and monitoring of icu-acquired weakness

icu-acquired weakness (icu-aw) is a prevalent complication, occurring in more than 50% of icu patients, and has severe long-term effects on patient outcomes. this condition not only prolongs the duration of hospital stay but also persists long after discharge, continuously impacting patients' health and quality of life. therefore, monitoring, prevention, and rehabilitation of icu-aw should not be limited to the icu period but should continue after transfer to general wards and after discharge. this study aims to provide foundational data for developing a platform capable of continuously monitoring and delivering rehabilitation therapy for icu-aw from icu admission through the post-discharge period. recent meta-analyses have shown that providing rehabilitation for icu patients improves physical function at discharge, reduces icu stay by 0.8 days, and shortens total hospital stay by 1.75 days. additionally, it increases the distance patients can walk unassisted at discharge, the number of patients capable of standing, the duration of ventilator-free days, and the percentage of patients discharged home. understanding the recovery process of icu-aw as a continuum from icu to post-discharge is essential, and the necessity of continuous rehabilitation throughout this process is evident. however, the challenge lies in implementing this in real-world practice. this study seeks to provide foundational data for developing personalized educational programs applicable to remote digital therapeutics in the future.

Eligibility criteria:
inclusion criteria: * patients admitted to the icu who are 19 years of age * patients who did consent of the study exclusion criteria: * patients with a history of peripheral nerve injury * patients with a history of major surgery within the past 12 weeks or those expected to undergo major surgery during the trial period * patients with a history of central nervous system disorders (e.g., stroke, spinal cord injury) * patients with cognitive impairment that may interfere with the conduct of the study * patients with do not resuscitate (dnr) orders, brain lesions, clinical frailty score (cfs) exceeding 4, or those who have undergone cardiopulmonary resuscitation * patients confirmed to have metastatic cancer

Keywords: post intensive care syndrome(pics) intensive care unit acquired weakness early mobilization digital health care device
effect of renal impairment on evobrutinib pharmacokinetics (pk)

Conditions: Renal Impairment

Summary: the study will investigate the pk and safety of evobrutinib in subjects with different degree of renal impairment as compared to subjects with normal renal function.


Eligibility criteria:
inclusion criteria: * male and female subjects with total body weight between 50.0 and 100.0 kilograms(kg) (inclusive) and body mass index (bmi) between 19.0 and 36.0 kg per meter square (inclusive) at the time of the screening examination * for subjects with impaired renal function: subjects must have an egfr according to the modification of diet in renal disease (mdrd) equation of less than 90 ml per minute at screening and the possibility of stratification to one of the groups and a stable renal function as defined by either: if the time interval between screening and dosing is greater than 10 days, two egfr with the second estimate within 20% of prior value or historical records of stable function over the past 3 months if within 20 percentage of screening value and within 10 days of dosing * other protocol defined inclusion criteria could apply exclusion criteria: * history or presence of respiratory, gastrointestinal (including bariatric or other gastric surgeries, or other conditions that may affect drug absorption) hepatic (including hepatorenal syndrome), hematological, lymphatic, neurological (including seizures), cardiovascular (including ventricular dysfunction and congestive heart failure), psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders that may affect the safety of the subject. * clinical history of any autoimmune disorder * prior history of cholecystectomy or splenectomy, and any clinically relevant surgery within 6 months prior to screening, which might interfere with the objectives of the study or the study procedures * history of any malignancy except superficial basal cell carcinoma treated for curative intent may be allowed * other protocol defined exclusion criteria could apply

Keywords: renal impairment evobrutinib pharmacokinetics
vestibulopathy, imbalance, and gait disturbances in parkinson disease

Conditions: Parkinson Disease

Summary: this study investigates whether vestibular (inner ear) dysfunction is a cause for poor balance in parkinson disease (pd), and whether inner ear stimulation with a small device may improve balance. this study will involve clinical testing, brain imaging, and an interventional treatment device for symptoms.

basic testing of participants began in november 2021, but using the device or sham will not begin prior to july 2022.

Eligibility criteria:
inclusion criteria: 1. parkinson disease duration of 5 years or more or hoehn \& yahr stage 1.5-4 exclusion criteria: 1. history of meniere disease or recent onset of acute vestibular dysfunction, such as otolith disorders (bbpv etc). 2. other disorders which may resemble pd, such as progressive supranuclear palsy (psp), vascular dementia, normal pressure hydrocephalus, multiple system atrophy (msa), corticobasal ganglionic degeneration, or toxic causes of parkinsonism. prototypical cases have distinctive clinical profiles, like early and severe dysautonomia (msa) or appendicular apraxia, which may differentiate them from idiopathic pd and psp. the use of the ukpdsbrc clinical diagnostic criteria for pd will mitigate the inclusion of subjects with atypical parkinsonism. 3. evidence of a stroke or mass lesion on structural brain imaging (mri). 4. participants in whom mri is contraindicated including, but not limited to, those with a pacemaker, presence of metallic fragments near the eyes or spinal cord, or cochlear implant. 5. severe claustrophobia precluding mr or pet imaging. 6. subjects limited by participation in research procedures involving ionizing radiation. 7. pregnancy (test within 48 hours of each pet session) or breastfeeding. 8. subjects with active and unstable mood or anxiety disorders 9. subjects with active ear infections or perforated eardrums
carotenoid rich diet in treating cervical dysplasia

Conditions: Cervical Cancer

Summary: rationale: a diet rich in carotenoids may be an effective treatment for cervical dysplasia. purpose: randomized phase ii trial to study the effectiveness of a carotenoid rich diet in treating patients with cervical dysplasia.

objectives: i. determine whether a carotenoid rich diet will cause a significant increase in the regression of disease in patients with grade i or ii cervical intraepithelial dysplasia. ii. determine whether the regression of disease in this patient population is reflected in the modulation of intermediate biological markers (viral genome copy number of human papilloma virus (hpv) and hpv e6/e7 expression). outline: this is a randomized, controlled study. patients are randomized to one of two treatment arms. arm i: patients receive dietary counseling and eat 5-10 servings of carotenoid rich fruit and vegetables each day for a year. arm ii: patients receive no counseling and maintain their normal diet. carotenoid levels, hpv status, progression of cervical dysplasia, and diet (by food frequency checklist and food diary) are monitored in both groups. projected accrual: a total of 240 patients will be accrued for this study within 5 years.

Eligibility criteria:
disease characteristics: histologically proven cervical intraepithelial dysplasia, grade cin ii, or cin i by repeat cytology no invasive carcinoma by pap smear no positive endocervical curettage patient characteristics: age: 18 to 55 (premenopausal) performance status: not specified life expectancy: not specified hematopoietic: not specified hepatic: not specified renal: not specified other: no concurrent beta carotene supplements not pregnant or nursing no prior malignancy prior concurrent therapy: biologic therapy: not specified chemotherapy: not specified endocrine therapy: not specified radiotherapy: not specified surgery: at least 6 months since prior cauterization, cryosurgery, laser, or conization of the cervix

Keywords: cervical cancer
oral health in covid-19 survivors

Conditions: COVID-19; Periodontitis

Summary: aims are to assess periodontal health and salivary stress/ immunity responses in covid-19 survivors

there are lack of data concerning oral health in covid-19 survivors, nevertheless, many middle-aged patients with oral symptoms of post-acute covid-19 report xerostomia and taste impairment and suffer from oral hypofunction, thus may be susceptible to periodontitis and oral frailty. post-acute or long covid-19 is/would be the health hallmark of post-covid-19 era, manifested as a multiplicity of clinical problems and requiring conceptual framework aiming at multidisciplinary health preserving activities. there are various factors which may affect oral and periodontal health in post-covid-19 era, such as disruption of dental professional care due to the fear of infection, virus-induced disturbance of oral homeostasis and, as a common denominator- covid-19-induced psychological stress. expected results would not just offer epidemiological data but also, mechanistic background for defining risks and modified measures aiming to preserve oral health in post-covid-19 era.

Eligibility criteria:
inclusion criteria: * self-reported good general health, ≥ 14 erupted teeth excluding third molars. for periodontally healthy: bleeding on probing score ≤10%, without attachment loss and radiographic bone loss and probing depth ≤ 3 mm in every site (trombelli l et al., 2018). for periodontitis patients: periodontitis in stages ii-iv. exclusion criteria: * history of periodontal treatment in previous six months, acute oral infection, presence of systemic disease(s), pregnancy, lactation, smoking ≥ 10 cigarettes per day
diode laser and green indocyanine in the non-surgical treatment of periodontitis

Conditions: Periodontitis

Summary: this is a parallel-group, randomized controlled clinical trial aimed to evaluate the clinical and microbiological effects of the adjunctive topical use of diode laser and green indocyanine in the full-mouth ultrasonic debridement of patients affected by periodontitis.

periodontitis is a chronic inflammatory disease affecting the supporting tissues of the teeth and is primarily caused by the subgingival inflammation induced by the bacterial oral biofilm. several risk factors may condition its development and progression and, if untreated, periodontitis may lead to tooth loss and severe functional and aesthetic impairments. a central role in the non-surgical treatment of periodontitis is played by the manual and ultrasonic debridement of supra and subgingival bacterial deposits. the benefit of a fully ultrasonic approach lies in the knowledge that removing radicular structure is not a prerequisite for periodontal healing. however, non-surgical therapy has limitations due to limited access to some sites (furcation areas, concavities, grooves, distal sites of molars, and deep pockets), which may impair periodontal healing due to the persistence of pathogens and subsequent recolonization. in this context, the use of diode laser in combination with photoactivated solutions has been proposed as an adjunct treatment to conventional periodontal therapy to enhance the antibacterial effect and improve clinical effects, especially in areas of difficult access. in view of theme relevance and the existence of conflicting results in the literature, the aim of the present parallel-group, randomized controlled clinical trial is to evaluate the clinical and microbiological effects of the adjunctive topical use of diode laser and indocyanine green (dlig) in the full-mouth ultrasonic debridement (fmud) of patients affected by periodontitis. 24 patients will be treated by fmud and, after 7 days, randomly allocated half to the test and a half to the control group. in the test group, patients will receive an adjunctive treatment in periodontal sites with an initial pocket depth \> 4mm consisting of the use of a diode laser device (fox arc, sweden \& martina, due carrare, italy) after pocket irrigation by a solution of indocyanine green (emundo®, sweden\&martina, due carrare, padova, italy), whereas the patients in the control group will receive sham treatment (st). the same treatment will be repeated three weeks after in both the test and control groups. clinical assessment and microbiological analysis of subgingival plaque will be performed at baseline and after 3 and 6 months.

Eligibility criteria:
inclusion criteria: * diagnosis of moderate to severe periodontitis * systemic health exclusion criteria: * systemic diseases requiring antibiotic prophylaxis or other systemic medication that could affect the patient's clinical response * periodontal treatment within the last 12 months or systemic antibiotic intake in the last 3 months * pregnancy